Research Group Identifies Over-Patenting Of Pharmaceuticals In India, Calls For Patent Reform 17/10/2018 by David Branigan, Intellectual Property Watch 2 Comments The tricontinental research group “accessibsa” has found that while the Indian Patent Office rejects 40 percent of pharmaceutical patent applications, it should be rejecting 90 percent of applications to comply with Indian patent law, according to the results of its recent study of Indian patent data.
South Africa: Copyright Amendment Bill Could Be Finished Next Month 17/09/2018 by Linda Daniels for Intellectual Property Watch Leave a Comment CAPE TOWN – The South Africa Parliament’s Portfolio Committee of Trade and Industry is expected to finalise the long-awaited Copyright Amendment Bill next month. But one more round of public comments is being sought in the meantime, with a deadline of this week.
African Health Ministers Approve Roadmap For Medicines Access, Framework To End Cholera 03/09/2018 by Catherine Saez, Intellectual Property Watch 1 Comment Health ministers from the World Health Organization Africa region last week endorsed a roadmap for access for the years 2019-2023 concerning areas such as fair pricing, intellectual property management, and supply chain management. The previous day, they pledged to implement key strategies to end cholera outbreaks in the African region by 2030.
Stakeholders Submit Views On South Africa Copyright Amendment 27/07/2018 by Linda Daniels for Intellectual Property Watch 1 Comment The call for public comments on the Copyright Amendment Bill by South Africa’s Parliamentary Portfolio Committee on Trade and Industry attracted a wide range of interest and contributions from local and international IP stakeholders.
South Africa’s Proposed Copyright Fair Use Right Should Be A Model For The World 24/07/2018 by Intellectual Property Watch 3 Comments Copyright laws the world over are under massive pressure to reform to fit the digital environment. One key area often in need of reform is in the exceptions to copyright that enable the digital practices. Without exceptions, common practices may be illegal, such as sharing photos on social media, making technical copies to send and stream, and uploading excerpts to closed networks for student access, writes a group of experts on the issue.
Deadline Looms For Comments On New Clauses In South African Copyright Amendment Bill 13/07/2018 by Linda Daniels for Intellectual Property Watch 1 Comment South Africa’s Portfolio Committee on Trade and Industry in Parliament has published a list of select clauses of the Copyright Amendment Bill for public comment. The deadline for comments is 18 July.
Legislation For South Africa’s New IP Policy Likely After Elections Next Year 11/06/2018 by Linda Daniels for Intellectual Property Watch 1 Comment Legislative changes giving effect to South Africa’s recently published Intellectual Property Policy “Phase 1” will not take place during this term of government, the country’s trade minister has said. Meanwhile, a side-by-side comparison with the 2017 draft legislation shows a series of changes in the final policy, and the pharmaceutical industry is complaining but appears determined to continue investing in the country.
New South African IP Policy Text Now Available 31/05/2018 by Intellectual Property Watch Leave a Comment The new Intellectual Property Policy of South Africa has now been posted to a government website.
South Africa Approves New IP Policy, With Guidance From UN Agencies 27/05/2018 by Linda Daniels for Intellectual Property Watch 3 Comments It took nine years of policy development, two different draft policies and various rounds of public consultation, to finally see Cabinet give the nod to the new Intellectual Property (IP) policy in South Africa.
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 by Catherine Saez, Intellectual Property Watch 14 Comments Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries, civil society organised itself to increase access to sofosbuvir for millions in need.